A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor
SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate
response to conventional synthetic DMARDs.